RxDoctor Payments Data

Karen Chavez Jones, APRN

Primary Care · Kenner, LANPI 1538713649

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.

$3,894in general payments, 2019–2025

Across 53 payments — averaging $73.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$617
  • Dexcom, Inc.$445
  • Abbott$315
  • Novo Nordisk$262
  • Viiv Healthcare Company$243
  • Sanofi$240
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$3,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,894 in reported general payments places this provider in the 85th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,164
Medicare patients
125
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$22,811
Levocetirizine Dihydrochloride72$852
Atorvastatin Calcium51$662
Albuterol Sulfate HfaAlbuterol Sulfate13$541
Valsartan11$403
Famotidine17$385
Pantoprazole Sodium29$335
Losartan Potassium38$328
Nifedipine ErNifedipine12$296
Fluticasone Propionate23$289
Metoprolol Succinate41$264
Gabapentin17$218
Omeprazole14$217
Amlodipine Besylate37$214
Pravastatin Sodium11$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$262$22,81118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 primary care providers in Louisiana.

Other primary care in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →